Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
Chem Res Toxicol. 2010 Jun 21;23(6):1018-24. doi: 10.1021/tx900367p.
(R)-Thalidomide was oxidized to 5-hydroxythalidomide and 5'-hydroxythalidomide by NADPH-fortified liver microsomes from humans and monkeys. (R)-Thalidomide was hydroxylated more efficiently than (S)-thalidomide. Recombinant human P450s 3A4, 3A5, and 3A7 and monkey P450s 3A8 and 3A5 (coexpressed with NADPH-P450 reductase in bacterial membranes) also catalyzed (R)-thalidomide 5-hydroxylation. Purified human P450s 2C19, 3A4, and 3A5 mediated (R)-thalidomide 5-hydroxylation at similar rates in reconstituted systems. P450 2C19 showed a rather nonsaturable substrate-velocity curve; however, P450s 3A4 and 3A5 showed sigmoidal curves. P450 also oxidized 5-hydroxythalidomide to an epoxide or dihydroxy compound. Liquid chromatography-mass spectrometry analysis revealed the formation of a glutathione conjugate from (R)- and (S)-5-hydroxythalidomide, catalyzed by liver microsomal P450s 3A4 and 3A5 in the presence of glutathione (assigned as a conjugate of 5-hydroxythalidomide formed on the phenyl ring). These results indicate that human P450s 3A4 and 3A5 mediate thalidomide 5-hydroxylation and further oxidation leading to a glutathione conjugate, which may be of relevance in the pharmacological and toxicological actions of thalidomide.
(R)-沙利度胺被人源和猴源肝微粒体中的 NADPH 增强型酶氧化为 5-羟沙利度胺和 5'-羟沙利度胺。(R)-沙利度胺比(S)-沙利度胺更有效地被羟化。重组人 P450s 3A4、3A5 和 3A7 以及猴 P450s 3A8 和 3A5(在细菌膜中与 NADPH-P450 还原酶共表达)也催化(R)-沙利度胺 5-羟化。在重组系统中,纯化的人 P450s 2C19、3A4 和 3A5 以相似的速率介导(R)-沙利度胺 5-羟化。P450 2C19 显示出相当非饱和的底物-速度曲线;然而,P450s 3A4 和 3A5 显示出 S 形曲线。P450 还氧化 5-羟沙利度胺生成环氧化物或二羟基化合物。液质联用分析表明,在谷胱甘肽存在的情况下,肝微粒体 P450s 3A4 和 3A5 催化(R)-和(S)-5-羟沙利度胺形成谷胱甘肽缀合物(被指定为苯环上形成的 5-羟沙利度胺的缀合物)。这些结果表明,人 P450s 3A4 和 3A5 介导沙利度胺 5-羟化和进一步氧化生成谷胱甘肽缀合物,这可能与沙利度胺的药理学和毒理学作用有关。